Does SSRI have a neuroprotective effect in patent after ischemic stroke?

Agata Rocka, Dominika Madras, Faustyna Piędel, Patryk Jasielski, Klaudia Szumna



Introduction and purpose:

Ischemic stroke accounts for the majority of all stroke cases, with recurrence rates of around 12% within the first year, rising to around 30% within five years.

Thrombolytic therapy based on the intravenous administration of rtPA (recombinant plasminogen activator) is the only treatment that has been proven to improve treatment outcomes after ischemic stroke. New methods that would increase the number of motor function returns are still being sought.

A brief description of the state of knowledge: 

SSRIs, selective serotonin reuptake inhibitors are used primarily in the treatment of depression and emotional lability after stroke. Many clinical and preclinical studies have suggested that SSRIs have a beneficial effect on the outcomes of stroke patients.

Our work is a brief overview of the current knowledge and clinical trials conducted. Review of the available literature using the PubMed database. Search criteria for scientific articles published from 2010 to 2020, search term: "SSRI ischaemic stroke". Ultimately, 12 randomized clinical trials were analyzed (3 articles apply for one study). One of the studies does not have unequivocal results.


Conclusions: The safety of SSRIs in stroke patients has been confirmed. Further multi-center studies are required to investigate the neuroprotective role of SSRIs.


SSRIж strokeж neuroprotective effect

Full Text:


References (Accesed: 25.07.2020).

Writing Group Members, Mozaffarian D, Benjamin EJ, et al. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association [published correction appears in Circulation. 2016 Apr 12;133(15):e599]. Circulation. 2016;133(4):e38-e360. doi:10.1161/CIR.0000000000000350.

Sacco RL, Kasner SE, Broderick JP, et al. An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association [published correction appears in Stroke. 2019 Aug;50(8):e239]. Stroke. 2013;44(7):2064-2089. doi:10.1161/STR.0b013e318296aeca.

Feigin VL , Krishnamurthi RV, Parmar P, Norrving B, Mensah GA, Bennett DA, et al. Update on the global burden of ischemic and hemorrhagic stroke in 1990–2013: the GBD 2013 study. Neuroepidemiology2015; 45: 161–76.

Gooch CL, Pracht E, Borenstein AR. The burden of neurological disease in the United States: A summary report and call to action. Ann Neurol. 2017;81(4):479-484. doi:10.1002/ana.24897. (Accesed: 18.07.2020).

Neuhaus AA, Couch Y, Hadley G, Buchan AM. Neuroprotection in stroke: the importance of collaboration and reproducibility. Brain. 017;140(8):2079-2092. doi:10.1093/brain/awx126.

Prabhakaran S, Ruff I, Bernstein RA. Acute stroke intervention: a systematic review. JAMA. 2015;313(14):1451-1462. doi:10.1001/jama.2015.3058.

Chollet F, Tardy J, Albucher JF. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol. 2011;10:123–130.

Chollet F, Rigal J, Marque P, et al. Serotonin Selective Reuptake Inhibitors (SSRIs) and Stroke. Curr Neurol Neurosci Rep. 2018;18(12):100. Published 2018 Oct 23. doi:10.1007/s11910-018-0904-9.

Taguchi N, Nakayama S, Tanaka M. Fluoxetine has neuroprotective effects after cardiac arrest and cardiopulmonary resuscitation in mouse. Resuscitation. 2012;83(5):652-656. doi:10.1016/j.resuscitation.2011.11.004.

Zhou S, Liu S, Liu X, Zhuang W. Selective serotonin reuptake inhibitors for functional independence and depression prevention in early stage of post-stroke: A meta-analysis. Medicine (Baltimore). 2020;99(6):e19062. doi:10.1097/MD.0000000000019062.

M.T. Wang, C.L. Chu, C.B. Yeh, et al. Antidepressant use and risk of recurrent stroke: a population-based nested case-control study. J. Clin. Psychiatry, 76 (2015), pp. e877-e885.

Damsbo AG, Kraglund KL, Buttenschøn HN, Johnsen SP, Andersen G, Mortensen JK. Serotonergic Regulation and Cognition after Stroke: The Role of Antidepressant Treatment and Genetic Variation. Cerebrovasc Dis. 2019;47(1-2):72-79. doi:10.1159/000498911.

Kraglund KL, Mortensen JK, Damsbo AG, et al. Neuroregeneration and Vascular Protection by Citalopram in Acute Ischemic Stroke (TALOS). Stroke. 2018;49(11):2568-2576. doi:10.1161/STROKEAHA.117.020067.

Kraglund KL, Mortensen JK, Grove EL, Johnsen SP, Andersen G. TALOS: a multicenter, randomized, double-blind, placebo-controlled trial to test the effects of citalopram in patients with acute stroke. Int J Stroke. 2015;10(6):985-987. doi:10.1111/ijs.12485.

Kraglund KL, Mortensen JK, Johnsen SP, Andersen G, Grove EL. Antiplatelet effects of citalopram in patients with ischaemic stroke: A randomized, placebo-controlled, double-blind study. Sci Rep. 2019;9(1):20048. Published 2019 Dec 27. doi:10.1038/s41598-019-56487-8.

Bonin Pinto C, Morales-Quezada L, de Toledo Piza PV, et al. Combining Fluoxetine and rTMS in Poststroke Motor Recovery: A Placebo-Controlled Double-Blind Randomized Phase 2 Clinical Trial. Neurorehabil Neural Repair. 2019;33(8):643-655. doi:10.1177/1545968319860483.

FOCUS Trial Collaboration. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. Lancet. 2019;393(10168):265-274. doi:10.1016/S0140-6736(18)32823-X.

Asadollahi M, Ramezani M, Khanmoradi Z, Karimialavijeh E. The efficacy comparison of citalopram, fluoxetine, and placebo on motor recovery after ischemic stroke: a double-blind placebo-controlled randomized controlled trial. Clin Rehabil. 2018;32(8):1069-1075. doi:10.1177/0269215518777791.

Savadi Oskouie D, Sharifipour E, Sadeghi Bazargani H, et al. Efficacy of Citalopram on Acute Ischemic Stroke Outcome: A Randomized Clinical Trial. Neurorehabil Neural Repair. 2017;31(7):638-647. doi:10.1177/1545968317704902.

Chollet F, Tardy J, Albucher JF, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial [published correction appears in Lancet Neurol. 2011 Mar;10(3):205]. Lancet Neurol. 2011;10(2):123-130. doi:10.1016/S1474-4422(10)70314-8.

He Y, Cai Z, Zeng S, et al. Effect of fluoxetine on three-year recurrence in acute ischemic stroke: A randomized controlled clinical study. Clin Neurol Neurosurg. 2018;168:1-6. doi:10.1016/j.clineuro.2018.02.029.

He YT, Tang BS, Cai ZL, Zeng SL, Jiang X, Guo Y. Effects of Fluoxetine on Neural Functional Prognosis after Ischemic Stroke: A Randomized Controlled Study in China. J Stroke Cerebrovasc Dis. 2016;25(4):761-770. doi:10.1016/j.jstrokecerebrovasdis.2015.11.035.

Guo Y, He Y, Tang B, et al. Effect of using fluoxetine at different time windows on neurological functional prognosis after ischemic stroke. Restor Neurol Neurosci. 2016;34(2):177-187. doi:10.3233/RNN-150535.

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM

Journal of Education, Health and Sport formerly Journal of Health Sciences

Declaration on the original version.

Editors indicates that the main version of the magazine is to issue a "electronic".

The journal has had 5 points in Ministry of Science and Higher Education parametric evaluation. § 8. 2) and § 12. 1. 2) 22.02.2019.

1223 Journal of Education, Health and Sport eISSN 2391-8306 7

ISSN 2391-8306 formerly ISSN: 1429-9623 / 2300-665X

Archives 2011 - 2014

PBN 2011 - 2014

POL-index 2011 - 2014

BASE 2011 - 2014

Indexed in Bases, Bazy indeksacyjne: ERIH Plus, Worldcat, PBN/POL-Index, ICI Journals Master List, Directory of Open Access Journals (DOAJ), ZBD, Ulrich's periodicals, Google Scholar, Polska Bibliografia Lekarska, EuroPub database, NLM Catalog Result - NCBI, BASE, Russian Sciences Index, Arianta.

US NLM = 101679844

101679844 - NLM Catalog Result - NCBI

Find a library that holds this journal:


PBN Poland



Redaction, Publisher and Editorial Office

Publisher and Editorial Office
Department of Physical Culture,
Faculty of Earth Sciences and Spatial Management,
Nicolaus Copernicus University in Toruń, Poland
Address: Str. Lwowska 1, 87-100 Toruń, Poland

  Open Access ISSN 2391-8306 formerly ISSN: 1429-9623 / 2300-665X

The journal has been approved for inclusion in ERIH PLUS.

The ERIH PLUS listing of the journal is available at

Indexed in Index Copernicus Journals Master List.,p24782242,3.html

ICV 2019 = 100.00 ICV 2018 = 95.95 ICV 2017 = 91.30 ICV 2016 = 84.69 ICV 2015 = 93.34 ICV 2014 = 89.51 Standardized Value: 8.27 ICV 2013: 7.32 ICV 2012: 6.41 ICV 20115.48

RG Journal Impact: 0.18 *

*This value is calculated using ResearchGate data and is based on average citation counts from work published in this journal. The data used in the calculation may not be exhaustive.

RG Journal impact history

2020Available summer 2021
2018 / 20190.18

RG Journal impact over time

RG Journal impact

Indexed in Polish Scholarly Bibliography (PBN) (PBN Polska Bibliografia Naukowa) (

is a portal of the Polish Ministry of Science and Higher Education, collecting information on publications of Polish scientists and on Polish and foreign scholarly journals. Polish Scholarly Bibliograhpy is a part of POL-on - System of Information on Higher Education. It is operated by the Interdisciplinary Centre for Mathematical and Computational Modelling, University of Warsaw.

Indexed in Russian Sciences Index Российский индекс научного цитирования (РИНЦ)

Indexed in Arianta Polish scientific and professional electronic journals Aneta Drabek i Arkadiusz Pulikowski


Partnerzy platformy czasopism